Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Markus Pfirrmann"'
Autor:
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Krämer, Christian Junghanss, Lars-Olof Mügge, Detlev Hähling, Carsten Hirt, Christian Späth, Norma Peter, Bernhard Opitz, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Pönisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schütte, Ralph Naumann, Hartmut Eimermacher, Bernd Dörken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Wörmann, Carsten Müller-Tidow, Hubert Serve, Christoph Schliemann, Rüdiger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, Verena S. Hoffmann
Publikováno v:
Annals of Hematology. 102:547-561
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arm
Autor:
Bernd Hertenstein, Rudolf Schlag, Nadine Pletsch, Susanne Saußele, Mathias Hänel, Stephan Kremers, Wolf-Karsten Hofmann, Rüdiger Hehlmann, Martin Wernli, Hartmut Link, Martin C. Müller, Stefan W. Krause, Gabriela M. Baerlocher, Annette Schreiber, Elisabeth Lange, Lida Kalmanti, Ulrike Proetel, Dominik Heim, Lothar Müller, Joerg Hasford, Hermann Einsele, Andreas Hochhaus, Michael Lauseker, Markus Pfirrmann, Benjamin Hanfstein
Publikováno v:
Annals of Hematology
Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C; Hanfstein, Benjamin; Krause, Stefan W; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; ... (2014). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of hematology, 93(7), pp. 1167-1176. Springer 10.1007/s00277-014-2041-0
Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C; Hanfstein, Benjamin; Krause, Stefan W; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; ... (2014). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of hematology, 93(7), pp. 1167-1176. Springer 10.1007/s00277-014-2041-0
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study i
Autor:
Martin C. Müller, Rüdiger Hehlmann, Markus Pfirrmann, Michael Lauseker, Joerg Hasford, Verena S. Hoffmann
Publikováno v:
Annals of hematology. 94(6)
Multi-state models support prediction in medicine. With different states of disease, chronic myeloid leukaemia (CML) is particularly suited for the application of multi-state models. In this article, we tried to find a model for CML that allows predi
Publikováno v:
Annals of hematology. 94
Nowadays in many fields of medicine, prognostic scores are used to predict the outcome for individual patients. In chronic myeloid leukemia (CML), the Sokal, the Euro, and the EUTOS score are established prognostic scores which were addressed by the
Autor:
Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Stefan W. Krause, Andreas Hochhaus, Dieter K. Hossfeld, Andreas Neubauer, Joerg Hasford, Cornelius F. Waller, Annette Schreiber, Lothar Kanz, Christiane Falge, Markus Pfirrmann, Christoph Nerl, Benjamin Hanfstein, Hans-Jochem Kolb, Jolanta Dengler, Michael Lauseker, Karsten Spiekermann, Lida Kalmanti, Ulrike Proetel, Susanne Schnittger, Alice Fabarius, Martin Müller, Dominik Heim, Frank Stegelmann, Michael Pfreundschuh, Rüdiger Hehlmann, Susanne Saussele
Publikováno v:
Annals of Hematology
Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in